Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Sponsor: Insel Gruppe AG, University Hospital Bern
Summary
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Official title: Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
350
Start Date
2026-04-01
Completion Date
2028-08-31
Last Updated
2026-03-30
Healthy Volunteers
No
Interventions
Stockholm3
Predictive value of Stockholm3 test in a prostate cancer cohort on Active Surveillance (AS) for upgrading on re-biopsy
Locations (1)
Inselspital, University Hospital of Bern
Bern, Canton of Bern, Switzerland